Fig. 8

Co-treatment of ATM inhibitor KU-55,933 or the PARP inhibitor olaparib with doxorubicin synergistically increases apoptosis of SIRT6-overexpressing osteosarcoma cells. U2OS and KHOS/NP cells were transfected with empty vector or wild-type SIRT6 and treated with DMSO, 10 µM KU-55,933, 30 µM olaparib, 0.1 µM doxorubicin, 0.1 µM doxorubicin and 10 µM KU-55,933, or 0.1 µM doxorubicin and 30 µM olaparib for 24 hours and flow-cytometry analysis performed with staining for propidium iodide and Annexin V. *; P < 0.05, **; P < 0.001